Photo Credit:
Speculation that an Israeli drug firm’s experimental drug will be able to treat Ebola has pushed up the stock price of Protalix Biotherapeutics nearly 50 percent this week.
The drug is based on a plant cell-based protein expression system.
Advertisement
Protalix was selling for less $2.20 cents last week and traded as high as $2.80 this week on the New York Stock Exchange.
Prof. Yoseph Sha’altiel, who invented Protalix’s technology, claimed last month that Protalix’s platform was suitable for producing the Ebola drug, but CEO David Aviezer later clarified that the drug sill is in the experimental stage.
The company’s shares are trading at 2.57 Thursday evening after having climbed to $2.75.
Advertisement